About Inivata
Inivata is a company based in Cambridge (United Kingdom) founded in 2014 was acquired by NeoGenomics in May 2021. Inivata has raised $188.79 million across 6 funding rounds from investors including NeoGenomics, Janus Henderson Investors and Farallon Capital Management. The company has 81 employees as of December 31, 2020. Inivata operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter Cambridge, United Kingdom
- Employees 81 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Inivata Limited
- Date of Incorporation 23 Jul, 2014
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
$816.09 K (USD)-40as on Dec 31, 2022
-
Net Profit
-$53.8 M (USD)12as on Dec 31, 2022
-
EBITDA
-$53.8 M (USD)12as on Dec 31, 2022
-
Total Equity Funding
$188.79 M (USD)
in 6 rounds
-
Latest Funding Round
$35 M (USD), Series C
Feb 04, 2021
-
Investors
NeoGenomics
& 12 more
-
Employee Count
81
as on Dec 31, 2020
-
Acquired by
NeoGenomics
(May 05, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Inivata
Unlock access to complete
Funding Insights of Inivata
Inivata has successfully raised a total of $188.79M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $35 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inivata
Inivata has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include NeoGenomics, Janus Henderson Investors and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital and advisory services are offered across multiple sectors.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Inivata
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inivata
Investment portfolio details for Inivata
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inivata
Detailed financials for Inivata
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inivata Comparisons
Peer comparison for Inivata
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inivata
Inivata operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
Non-invasive molecular diagnostic tests for cancer are developed using epigenetics.
|
Detailed competitors of Inivata
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inivata
Complete news archive for Inivata
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inivata
Inivata was founded in 2014.
Inivata is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Inivata is a funded company, having raised a total of $188.79M across 6 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Inivata is 81.
Annual revenue of Inivata is $816.09K as on Dec 31, 2022.
Inivata was founded in 2014 in Cambridge, United Kingdom, within the biotechnology sector. A liquid biopsy platform is provided by the company to detect cancer through next-generation sequencing. The proprietary TAm-Seq technology is employed to analyze large genomic regions, such as entire genes or exons, enhancing sensitivity and coverage beyond traditional approaches. Operations focus on a gene panel profiling 34 cancer-related genes for clinical applications.
Inivata's top competitors include Guardant Health, GRAIL and BillionToOne.
Inivata has 13 investors. Key investors include NeoGenomics, Janus Henderson Investors, Farallon Capital Management, IP Group, and European Union.